TriangleCetuximab (NCT04375384)
Cetuximab trial for Head and Neck Squamous Cell Carcinoma (NCT04375384). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or metastatic head-and-neck squamous cancer after PD1 immunotherapy, alone or with chemotherapy, failed or could not be tolerated. EGFR-directed therapy within five years excludes participation.
The idea: cetuximab blocks EGFR growth signaling. Researchers test it alone after immunotherapy, measuring tumor response and side effects. The first infusion delivers 400 milligrams per square meter over two hours; weekly maintenance delivers 250 milligrams per square meter over one hour.
This phase 2 study plans 38 patients. Mercedes Porosnicu leads at Wake Forest, Winston-Salem, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.